ReviewBiomedicines2022
A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Nailfold Capillaroscopic Changes in Children with Atopic Dermatitis.Journal of clinical medicine · 2026Article
- Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics.Medical sciences (Basel, Switzerland) · 2026Review
- Topical Anti-Inflammatory Effects of Quercetin Glycosides on Atopic Dermatitis-Like Lesions: Influence of the Glycone Type on Efficacy and Skin Absorption.Inflammation · 2025Article
- Exploring the role of the Th9/IL-9 axis in atopic dermatitis: analysis of Th9 cells, PU.1 expression and serum IL-9 levels.Immunologic research · 2025Article
- Histamine Metabolism in IBD: Towards Precision Nutrition.Nutrients · 2025Review
- Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review.Dermatology and therapy · 2025Review
- Langerhans cells: Central players in the pathophysiology of atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Efficacy of Upadacitinib in the Treatment of Acquired Reactive Perforating Collagenosis in a Patient with Type 1 Diabetes: A Case Report and A Literature Review.Clinical, cosmetic and investigational dermatology · 2025Article
- Symbiotic bacteria-mediated imbalance and repair of immune homeostasis: exploring novel mechanisms of microbiome-host interactions in atopic dermatitis.Frontiers in immunology · 2025Review
- Review
- Pharmacology of P2X Receptors and Their Possible Therapeutic Potential in Obesity and Diabetes.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Paediatric Atopic Dermatitis: The Unexpected Impact on Life with a Specific Look at the Molecular Level.International journal of molecular sciences · 2024Review
- SNG100, a novel topical treatment for moderate atopic dermatitis, in patients aged 6 years or older: A randomised, double-blind, active-controlled trial.Skin health and disease · 2023Article
- Diseases from the Spectrum of Dermatitis and Eczema: Can "Omics" Sciences Help with Better Systematics and More Accurate Differential Diagnosis?International journal of molecular sciences · 2023Review
- The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update.Frontiers in molecular biosciences · 2023Review
- Comprehensive Assessment of Symptoms, Comorbidities, and Treatment Response in Individuals with Atopic Dermatitis Treated at a Referral Centre between 2018 and 2022.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common chronic inflammatory and immune-mediated skin disease with a complex pathophysiology and still represents a therapeutic challenge, owing to limited responses to available treatments. However, recent advances in the understanding of AD pathophysiology have led to the discovery of several new potential therapeutic targets, and research in the field of new molecules with therapeutic perspectives is boiling, with more than 70 new promising drugs in development. The aim of this systematic review is to provide the state of the art on the current knowledge concerning the pathophysiology of the disease and on novel agents currently being investigated for AD, and to highlight which type of evolution is going to take place in therapeutic approaches of atopic dermatitis in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.